This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Sep-26 quarter, Rs lakh: revenue 440.69 vs 434.74 year ago; PAT fell to 51.01 from 81.78
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended 30 September 2026: revenue from operations was Rs 440.69 lakh and profit after tax Rs 51.01 lakh, versus Rs 434.74 lakh and Rs 81.78 lakh a year earlier. Operating profit margin before interest, depreciation and tax fell from 19.5 to 12.4 percent. Standalone half-year profit after tax was Rs 66.70 lakh versus Rs 120.78 lakh a year earlier. The board approved the unaudited results; review found no significant errors.
The quarter shows weaker profit and margins despite slightly higher revenue, which may put pressure on the share price.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹4.36 Cr | ₹4.29 Cr | +1.8% |
| Operating profit | ₹0.46 Cr | ₹0.76 Cr | −38.7% |
| Profit after tax | ₹0.51 Cr | ₹0.82 Cr | −37.6% |
| EBITDA margin | 11.5% | 18.3% | −6.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.